A pharmacokinetic model for voriconazole in a highly diversified population of children and adolescents with cancer.

Fabianne Altruda de Moraes Costa CarlesseOrlei Ribeiro de AraújoLeticia Maria Acioli MarquesDafne Cardoso Bourguignon da SilvaAndreza Almeida SenerchiaAntonio Sergio Petrilli

Published in: Mycoses (2019)

Extremely ill patients can be poor metabolizers of voriconazole. Therapeutic monitoring promotes only a limited improvement in drug management.

Keyphrases

end stage renal disease
newly diagnosed
chronic kidney disease
peritoneal dialysis
emergency department
squamous cell carcinoma
patient reported outcomes
young adults
childhood cancer